Skip to main content
Fig. 1 | Translational Medicine Communications

Fig. 1

From: Mesenchymal stem cells in the treatment of severe COVID-19

Fig. 1

Chest radiographs of patient prior to and following treatment with Mesenchymal Stem Cells (MSCs). Seventy-nine year old female, with MSC treatment 2 days post-admission; chest radiograph day 0 showing bilateral infiltrates (A) and 12 days post-treatment (B). Sixty-four year old critically severe male, radiograph on day of ventilation and MSC treatment (C). Marked improvement of infiltrates and extubation 8 days following initial MSC infusion (D). 73 year old critically severe male treated with MSCs 12 days after initial admission. Radiograph the day prior to MSC treatment (E) indicates pulmonary infiltrates, which improved by day 9 following MSC infusion (F). Sixty-one year old female categorized as critically severe COVID-19 on admission, treated with MSCs 4 days following admission. Chest x-rays one day prior to MSC infusions indicates severe pulmonary infection (G) which substantially improved by day 11 post-treatment (H). Eighty-four year old male treated with MSCs 11 days after admission. Pre-treatment radiograph (I) on day 11 shows mild worsening of patchy airspace opacities bilaterally. There was slow improvement over time and infiltrates reduced on day 22 following MSC treatment (J). 30 year old female treated with MSCs 57 days after admission. Pre-treatment radiograph (K) on day 56 shows stable severe diffuse multifocal pulmonary opacities and focal lucencies within both upper lung zones which may represent loculated pleural air or parenchymal cavitation. Infiltrates reduced on day 4 following MSC treatment (L)

Back to article page